D. J. Drucker, J. B. Buse, K. Taylor, D. M. Kendall, M. Trautmann, D. Zhuang, DURATION-1 Study Group, et al., “Exenatide Twice Daily versus Weekly Eleven for the Treatment of Type 2 Diabetes: A Randomized, Open-Label, Non-Inferiority Study,” Lancet, Vol. 372, 2008, pp. 1240-1250.
http://dx.doi.org/10.1016/S0140-6736(08)61206-4

has been cited by the following article:

• TITLE: Evolution of Biochemical Effects of Byetta® in Type 2 Diabetics with Cardiovascular Risk

  AUTHORS: Alfonso López Ruiz, María Ángeles Ibáñez Gil, Pedro Pujante Alarcón, Alicia Hernández Torres, Ana Belen Hernández Cascales, María Dolores Hellín Gil

  KEYWORDS: Diabetes Mellitus Type 2; Exenatide; Cardiovascular Risk

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.9, December 11, 2013

  ABSTRACT: The objective of this study was to examine longitudinally the effects of exenatide on different physical and biochemical markers, evaluated in adult type 2 diabetic patients with cardiovascular risk. Data were recorded from 10 patients who attended the outpatient primary care health center Mariano Iago Yecla, Murcia province, Spain in the period of December 2009 to October 2011 and who were treated with Byetta®. Differences were statistically significant (p 0.05) in HbA1c from the third month of treatment, and trends of decrease in body weight from the third week of treatment. There was a significant and better glycemic control. Overall effect was interpreted as a sensitizer drug of the parameters evaluated. Randomized studies are recommended with a minimum follow-up of 2 years, to see if the results are maintained over time.